Recent News Releases
For investor-related news, see our ASX releases here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
-
Mar 8, 2018
Updated label may allow for increased dosing flexibility for patients with hyperkalaemia Label update effective immediately in the US THE UNITED STATES (US) FOOD AND DRUG ADMINISTRATION (FDA) HAS...
-
Feb 8, 2018
VIFOR PHARMA ANNOUNCED TODAY THAT VIT-2763, THE FIRST-EVER ORAL FERROPORTIN INHIBITOR FOR PREVENTING IRON OVERLOAD WILL ENTER CLINICAL DEVELOPMENT WITH A PHASE-I STUDY AT THE BEGINNING OF MARCH...
-
Jan 4, 2018
Conditional marketing authorization application for treatment of patients with ANCA-associated vasculitis validated for start of procedure by EMA Significant milestone further strengthens Kidney...
-
Jan 4, 2018
Klicken Sie hier für Deutsch Veuillez cliquer ici pour français SWISSMEDIC HAS APPROVED PATIROMER TO BE MARKETED IN SWITZERLAND AS VELTASSA® FOR THE TREATMENT OF HYPERKALAEMIA (ELEVATED SERUM...
Dec 12, 2017Dr Brian McNamee AO and Mr Abbas Hussain have been appointed as independent Non-Executive Directors, effective 14 February 2018. CSL (ASX:CSL; USOTC:CSLLY) today announced that Dr Brian McNamee AO...